The 13 drugs for which CVS Caremark customers will have the option to sign up for genetic testing includes a range of treatments for cancer, HIV, and other indications, but the anticoagulant warfarin is not on the list.
CVS Caremark is increasing its investment in Generation Health for an undisclosed amount. Additionally, the CEO of the genetic benefits management firm, Per Lofberg, will now take over as president of CVS Caremark's PBM division.
In an attempt to help guide healthcare stakeholders who wish to issue public comments to the interim final GINA rule, Johns Hopkins University's Genetics & Public Policy Center released a model document discussing GINA's underwriting restrictions and how they impact health risk assessments and wellness programs.
While DMAA and employer groups are urging for a moratorium on GINA fearing that the law's restrictions on "underwriting" activities will harm enrollment in wellness programs, personalized medicine advocates are concerned that any delay in implementing the law as is would harm adoption of personalized medicine and hinder participation in genetic research studies.
As part of a deal struck with the genetics testing benefit management company, Generation Health, CVS Caremark plans to extend all of its PBM clients PGx testing for certain drugs as of the second quarter 2010.
Genetic benefit management company Generation Health will assist the nation’s largest pharmacy services provider, CVS Caremark, to extend pharmacogenomics testing services to its pharmacy benefit management customers.
Data from two national insurers, Humana and Aetna, shows that around 20 percent of requests for the test do not meet requirements for testing under their policy. A United Healthcare official has cited competitors' data suggesting that as much as 80 percent of requests for Myriad's BRCA test are withdrawn after pre-certification and genetic counseling procedures are conducted.